Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2019-03-01 Director's Dealing
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2019-03-01 English
SC 13G/A
Major Shareholding Notification
2019-02-14 English
SCHEDULE 13G/A
Major Shareholding Notification
2019-02-14 English
Regulatory Filings 2019
Regulatory Filings
2019-02-14 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering of up to $60 million. It includes detailed information about the offering, the sales agreement with Jefferies LLC, risk factors, use of proceeds, dividend policy, and plan of distribution. The document is a registration statement supplement for a securities offering, which is a capital raising activity. It is not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, confirming it is a full prospectus supplement related to financing.
2019-02-13 English
SC 13G/A
Major Shareholding Notification
2019-02-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.